CENTURA LONGMONT UNITED HOSPITAL
1. Target Overview & Investment Thesis
CENTURA LONGMONT UNITED HOSPITAL is a 127-bed under-performing / distressed in BOULDER, CO with $102.1M in net patient revenue and a -31.7% operating margin. The hospital serves a payer mix of 27.1% Medicare, 24.1% Medicaid, and 48.8% commercial.
Thesis: Undervalued. Our ML models identify $7.5M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -31.7% to -24.3% (+736bps).
| Net Revenue HCRIS | $102.1M |
| Current EBITDA COMPUTED | $-32.3M |
| Operating Margin COMPUTED | -31.7% |
| Occupancy HCRIS | 21.8% |
| Revenue / Bed COMPUTED | $804K |
| Net-to-Gross HCRIS | 17.3% |
| Distress Probability ML | 58.8% |
2. Market Context & Competitive Position
CO has 108 Medicare-certified hospitals with a median operating margin of -3.6%. The target's margin of -31.7% places it below the state median. Among 35 size-comparable peers (64-254 beds), the median margin is -1.3%. The target's below-peer margin suggests operational improvement opportunity.
3. RCM Performance Analysis — Comparable Hospitals
Comps selected by bed count (64-254), prioritizing same-state peers. 35 hospitals in the comp set.
| Hospital | State | Beds | Revenue | Margin |
|---|---|---|---|---|
| CENTURA LONGMONT UNITED HOSPIT (Target) | CO | 127 | $102.1M | -31.7% |
| POUDRE VALLEY HOSPITAL | CO | 218 | $722.4M | 10.8% |
| ST. MARYS HOSPITAL & MEDICAL C | CO | 237 | $554.0M | -11.0% |
| MEDICAL CENTER OF THE ROCKIES | CO | 180 | $541.1M | 11.6% |
| PARKVIEW MEDICAL CENTER | CO | 253 | $522.9M | 4.1% |
| CENTURA ST ANTHONY HOSPITAL | CO | 220 | $483.2M | 1.2% |
| BOULDER COMMUNITY HOSPITAL | CO | 139 | $418.3M | -1.6% |
| LUTHERAN MEDICAL CENTER | CO | 242 | $397.4M | -15.0% |
| CENTURA PARKER ADVENTIST HOSPI | CO | 162 | $351.5M | 12.9% |
4. Predicted Improvement Opportunities
Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $7.5M (736bps margin improvement).
| Lever | Current | Target | EBITDA Impact | Margin | Ramp |
|---|---|---|---|---|---|
| Net Collection Rate | 93.5% | 97.0% | $2.1M | +210bp | 18mo |
| Cost to Collect | 4.5% | 2.5% | $2.0M | +200bp | 12mo |
| Denial Rate Reduction | 12.0% | 6.5% | $2.0M | +198bp | 12mo |
| A/R Days Reduction | 5200.0% | 3800.0% | $1.2M | +122bp | 9mo |
| Clean Claim Rate | 88.0% | 96.0% | $65K | +6bp | 6mo |
5. EBITDA Bridge
| Current EBITDA | $-32.3M |
| + RCM Uplift | +$7.5M |
| Pro Forma EBITDA | $-24.8M |
| Current Margin | -31.7% |
| Pro Forma Margin | -24.3% |
| WC Released (1x) | $3.9M |
6. Returns Analysis — Scenario Matrix
5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.
| Scenario | Entry | Exit | Equity In | Equity Out | MOIC | IRR |
|---|---|---|---|---|---|---|
| Base Case | 10.0x | 10.0x | $-49.8M | $-138.2M | 0.00x | -100.0% |
| Base (11x exit) | 10.0x | 11.0x | $-49.8M | $-168.2M | 0.00x | -100.0% |
| Bull Case | 9.0x | 11.0x | $-44.8M | $-159.6M | 0.00x | -100.0% |
| Bull (12x exit) | 9.0x | 12.0x | $-44.8M | $-187.3M | 0.00x | -100.0% |
| Bear Case | 11.0x | 10.0x | $-54.7M | $-159.6M | 0.00x | -100.0% |
| Bear (11x exit) | 11.0x | 11.0x | $-54.7M | $-193.4M | 0.00x | -100.0% |
7. Key Risks & Mitigants
| Severity | Risk Factor | Mitigant |
|---|---|---|
| High | Negative operating margin | RCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion |
| Medium | Elevated Medicaid exposure (24.1%) | Medicaid reimburses below cost in most states. Mitigant: denial reduction lever has highest impact on Medicaid claims |
| Medium | Low occupancy | At 21.8%, fixed costs are spread over fewer patient days. Mitigant: volume growth is an additional upside lever not modeled in base case |
| High | Elevated distress probability | Model estimates 58.8% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk |
| Low | Low net-to-gross ratio | Large contractual allowances suggest pricing discipline issues. Mitigant: payer renegotiation is an additional upside lever |
8. Data Sources & Methodology Appendix
Data Sources
- CMS HCRIS Cost Reports (Medicare-certified hospitals)
- CMS Medicare Utilization (DRG-level volumes)
- CMS Chronic Conditions (county-level disease prevalence)
- HCRIS multi-year trend data (financial time series)
Comparable Selection
- 35 hospitals with 64-254 beds
- Same-state prioritization (n=36)
- Comp margins: P25=-10.4% / P50=-1.3% / P75=7.5%
Bridge Methodology
- Targets: P75 of comparable peers (60% gap closure)
- Denial: avoidable share = 35% of delta × NPR
- AR: bad debt coefficient = $0.65 per day per $1K NPR
- NCR: 60% coefficient on collection rate improvement
- CDI: 0.75% of Medicare revenue per 0.01 CMI point
Returns Assumptions
- Leverage: 5.5x entry (84.6% debt / 15.4% equity)
- Organic growth: 3% annual EBITDA growth
- Debt paydown: 10% of principal per year
- Hold period: 5 years
Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.